National Institute of General Medical Sciences; Notice of Meeting, 41712-41713 [E9-19663]
Download as PDF
<![CDATA[
41712
Federal Register / Vol. 74, No. 158 / Tuesday, August 18, 2009 / Notices
jlentini on DSKJ8SOYB1PROD with NOTICES
ACTION: Notice; reopening of comment
period.
SUMMARY: The Food and Drug
Administration (FDA) is reopening until
November 6, 2009, the comment period
for the notice of public meeting and
request for comments that appeared in
the Federal Register of June 3, 2009 (74
FR 26712). In the notice of public
meeting and request for comments,
FDA’s Transparency Task Force
requested comments on ways in which
FDA can make useful and
understandable information about FDA
activities and decision making more
readily available to the public. The
agency is taking this action because the
agency is planning a second public
meeting this fall and is reopening the
comment period to allow interested
persons additional time to submit
comments.
DATES: Submit written or electronic
comments by November 6, 2009.
ADDRESSES: Submit written comments
to the Division of Dockets Management
(HFA–305), Food and Drug
Administration, 5630 Fishers Lane, rm.
1061, Rockville, MD 20852. Submit
electronic comments to https://
www.regulations.gov. All such
comments should be identified with the
docket number found in brackets in the
heading of this document.
FOR FURTHER INFORMATION CONTACT: Afia
Asamoah, Office of the Commissioner,
Food and Drug Administration, 10903
New Hampshire Ave., Bldg. 1, rm. 2208,
Silver Spring, MD 20993, 301–796–
4625, FAX: 301–847–3531, e-mail:
Afia.Asamoah@fda.hhs.gov.
SUPPLEMENTARY INFORMATION: In the
Federal Register of June 3, 2009 (74 FR
26712), FDA published a notice of
public meeting and request for
comments on ways in which FDA can
make useful and understandable
information about FDA activities and
decisionmaking more readily available
to the public, in a manner compatible
with the agency’s goal of protecting
confidential information, as appropriate.
Interested persons were given until
August 7, 2009, to submit comments.
The agency is planning to hold a second
meeting in the fall of 2009 about these
issues and is reopening the comment
period until November 6, 2009. FDA has
also established an online blog at https://
fdatransparencyblog.fda.gov in which
interested persons may provide
feedback on specific topics. The blog is
expected to run through November
2009.
Interested persons may submit written
or electronic comments to the Division
of Dockets Management (see
VerDate Nov<24>2008
16:30 Aug 17, 2009
Jkt 217001
ADDRESSES).
Submit a single copy of
electronic comments to https://
www.reguations.gov or two paper copies
of any mailed comments, except that
individuals may submit one paper copy.
Comments are to be identified with the
docket number found in brackets in the
heading of this document. Received
comments may be seen in the Division
of Dockets Management between 9 a.m.
and 4 p.m., Monday through Friday.
Dated: August 12, 2009.
Jeffrey Shuren,
Associate Commissioner for Policy and
Planning.
[FR Doc. E9–19778 Filed 8–17–09; 8:45 am]
BILLING CODE 4160–01–S
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Board of Scientific Counselors,
National Center for Public Health
Informatics (BSC, NCPHI)
In accordance with section 10(a)(2) of
the Federal Advisory Committee Act
(Pub. L. 92–463), the Centers for Disease
Control and Prevention (CDC),
announces the following meeting of the
aforementioned committee:
Time and Date: 8:30 a.m.–5 p.m.,
September 2, 2009.
Place: Hyatt Regency, 265 Peachtree
Street NE., Atlanta, Georgia, 30303 Tel:
(404) 577–1234, Fax: (404) 588–4137.
Maps & Directions
This meeting will also be
teleconferenced: Toll Free Number:
(866) 713–5586, Participant’s pass code
4624038.
Status: Open to the public, limited
only by the space available.
Purpose: The committee shall advise
the Secretary, HHS, and the Director,
CDC, concerning strategies and goals for
the programs and research within the
national centers; shall conduct peerreview of scientific programs; and
monitor the overall strategic direction
and focus of the national centers. The
board, after conducting its periodic
reviews, shall submit a written
description of the results of the review
and its recommendations to the
Director, CDC. The board shall perform
second-level peer review of applications
for grants-in-aid for research and
research training activities, cooperative
agreements, and research contract
proposals relating to the broad areas
within the national center.
Matters to be Discussed: The board
will discuss BSC, NCPHI-related
PO 00000
Frm 00039
Fmt 4703
Sfmt 4703
matters, including an update on NCPHI
Programs and other BSC-related
activities.
Agenda items are subject to change as
priorities dictate.
Contact Person for More Information:
Dr. Scott McNabb, National Center for
Public Health Informatics, CDC, 1600
Clifton Road, NE., Mailstop E–78,
Atlanta, Georgia 30333, Telephone (404)
498–6427, Fax (404) 498–6235.
The Director, Management Analysis
and Services Office, has been delegated
the authority to sign Federal Register
notices pertaining to announcements of
meetings and other committee
management activities for both the CDC
and the Agency for Toxic Substance and
Disease Registry.
Dated: August 10, 2009.
Elaine L. Baker,
Director, Management Analysis and Services
Office, Centers for Disease Control and
Prevention.
[FR Doc. E9–19754 Filed 8–17–09; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of General Medical
Sciences; Notice of Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of a meeting of the
National Advisory General Medical
Sciences Council.
The meeting will be open to the
public as indicated below, with
attendance limited to space available.
Individuals who plan to attend and
need special assistance, such as sign
language interpretation or other
reasonable accommodations, should
notify the Contact Person listed below
in advance of the meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Advisory
General Medical Sciences Council.
Date: September 10–11, 2009.
Closed: September 10, 2009, 8:30 a.m. to 5
p.m.
E:\FR\FM\18AUN1.SGM
18AUN1
Federal Register / Vol. 74, No. 158 / Tuesday, August 18, 2009 / Notices
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Natcher Building, Conference Rooms E1 &
E2, 45 Center Drive, Bethesda, MD 20892.
Open: September 11, 2009, 8:30 a.m. to
adjournment.
Agenda: For the discussion of program
policies and issues, opening remarks, report
of the Director, NIGMS, and other business
of the Council.
Place: National Institutes of Health,
Natcher Building, Conference Rooms E1 &
E2, 45 Center Drive, Bethesda, MD 20892.
Contact Person: Ann A. Hagan, PhD,
Associate Director for Extramural Activities,
NIGMS, NIH, DHHS, 45 Center Drive, Room
2AN24H, MSC6200, Bethesda, MD 20892–
6200. (301) 594–4499.
hagana@nigms.nih.gov.
Any interested person may file written
comments with the committee by forwarding
the statement to the Contact Person listed on
this notice. The statement should include the
name, address, telephone number and when
applicable, the business or professional
affiliation of the interested person.
In the interest of security, NIH has
instituted stringent procedures for entrance
onto the NIH campus. All visitor vehicles,
including taxicabs, hotel, and airport shuttles
will be inspected before being allowed on
campus. Visitors will be asked to show one
form of identification (for example, a
government-issued photo ID, driver’s license,
or passport) and to state the purpose of their
visit.
Information is also available on the
Institute’s/Center’s home page: https://
www.nigms.nih.gov/about/
advisory_council.html, where an agenda and
any additional information for the meeting
will be posted when available.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.375, Minority Biomedical
Research Support; 93.821, Cell Biology and
Biophysics Research; 93.859, Pharmacology,
Physiology, and Biological Chemistry
Research; 93.862, Genetics and
Developmental Biology Research; 93.88,
Minority Access to Research Careers; 93.96,
Special Minority Initiatives, National
Institutes of Health, HHS)
Dated: August 10, 2009.
Jennifer Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. E9–19663 Filed 8–17–09; 8:45 am]
BILLING CODE 4140–01–M
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
jlentini on DSKJ8SOYB1PROD with NOTICES
[Docket No. FDA–2009–N–0376]
Office of the Commissioner
Reorganization; Statement of
Organizations, Functions, and
Delegations of Authority
AGENCY:
Food and Drug Administration,
HHS.
VerDate Nov<24>2008
16:30 Aug 17, 2009
Jkt 217001
ACTION:
Notice.
SUMMARY: The Food and Drug
Administration (FDA) has reorganized
the Office of the Commissioner (OC).
This reorganization includes the
organizations and their substructure
components as listed in this document.
This reorganization includes the realignment of four Deputy-level offices
within the Office of the Commissioner:
the Office of the Chief Scientist; the
Office of Administration (formerly titled
the Office of Operations); the Office of
Foods; and the Office of Policy,
Planning and Budget (formerly titled the
Office of Policy, Planning and
Preparedness).
FOR FURTHER INFORMATION CONTACT:
Vanessa Starks, Office of Management
Programs (HFA–400), Food and Drug
Administration, 5600 Fishers Lane, rm.
6B–42, Rockville, MD 20857, 301–827–
1463.
Office of the Chief Scientist: The
organizational change will allow the
agency to better focus the science and
research activities under the Chief
Scientist. Re-alignments under the
Office of the Chief Scientist will include
the Office of Counter-Terrorism and
Emerging Threats, Office of Critical Path
Programs, Office of Scientific Integrity,
and the Office of Science and
Innovation.
Office of Administration: The Office
of Operations will be re-titled the Office
of Administration. The Office of
Administration will be restructured to
strengthen agency wide management
programs, budget and shared services
operations, as well as the Office of the
Commissioner’s executive operations.
Realignments of the Office of
Acquisitions and Grants Services, the
Office of Executive Operations, the
Office of Information Management, the
Office of Management, the Office of
Equal Employment Opportunity and
Diversity Management, and the
establishment of the Office of Financial
Operations.
Office of Foods: The Office of Foods
will be realigned from the Office of
Operations and will report directly to
the Commissioner.
Office of Policy, Planning and Budget:
The Office of Policy, Planning and
Preparedness will be retitled the Office
of Policy, Planning and Budget. The
realignments from the Office of Policy,
Office of Planning, and the Office of
Budget Formulation (formerly titled the
Office of Budget Formulation and
Presentation, Office of Operations).
[Part D, Chapter D–B, (Food and Drug
Administration), the Statement of
Organization, Functions, and
Delegations of Authority for the
PO 00000
Frm 00040
Fmt 4703
Sfmt 4703
41713
Department of Health and Human
Services (35 FR 3685, February 25,
1970, and 60 FR 56605, November 9,
1995, 64 FR 36361, July 6, 1999, 72 FR
50112, August 30, 2007) is amended to
reflect the restructuring of the Office of
the Commissioner (OC), Food and Drug
Administration (FDA) as follows].
I. Under Part D, Food and Drug
Administration, delete the Office of
Commissioner in its entirety and replace
with the following:
DA.10 ORGANIZATION. The Food
and Drug Administration (FDA) is
headed by the Commissioner, Food and
Drug, and includes the following
organizational units:
Office of the Commissioner
Office of the Chief Counsel
Office of the Chief of Staff
Office of Legislation
Office of Policy, Planning and Budget
Office of Counselor to the
Commissioner
Office of Women’s Health
Office of Special Medical Programs
Office of External Affairs
Office of Foods
Office of the Chief Scientist
Office of International Programs
Office of Administration
Office of Equal Employment
Opportunity and Diversity Management
Center for Tobacco Products
DA.20 FUNCTIONS.
Office of the Commissioner: The
Office of the Commissioner (OC)
includes the Commissioner and Deputy
Commissioner who are responsible for
the efficient and effective
implementation of the FDA mission.
Office of the Chief Counsel: The
Office of the Chief Counsel (OCC) is also
known as the Food and Drug Division,
Office of the General Counsel,
Department of Health and Human
Services. While administratively within
the Office of the Commissioner, the
Chief Counsel is part of the Office of the
General Counsel of the Department of
Health and Human Services.
1. Is subject to the professional
supervision and control of the General
Counsel, Department of Health and
Human Services (DHHS), and represents
FDA in court proceedings and
administrative hearings with respect to
programs administered by FDA.
2. Provides legal advice and policy
guidance for programs administered by
FDA.
3. Acts as liaison to the Department of
Justice and other Federal agencies for
programs administered by FDA.
4. Drafts or reviews all proposed and
final regulations and Federal Register
notices prepared by FDA.
5. Performs legal research and gives
legal opinions on regulatory issues,
actions, and petitions submitted to FDA.
E:\FR\FM\18AUN1.SGM
18AUN1
]]>Agencies
[Federal Register Volume 74, Number 158 (Tuesday, August 18, 2009)]
[Notices]
[Pages 41712-41713]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E9-19663]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute of General Medical Sciences; Notice of Meeting
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is hereby given of a meeting of the
National Advisory General Medical Sciences Council.
The meeting will be open to the public as indicated below, with
attendance limited to space available. Individuals who plan to attend
and need special assistance, such as sign language interpretation or
other reasonable accommodations, should notify the Contact Person
listed below in advance of the meeting.
The meeting will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Advisory General Medical Sciences
Council.
Date: September 10-11, 2009.
Closed: September 10, 2009, 8:30 a.m. to 5 p.m.
[[Page 41713]]
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Natcher Building,
Conference Rooms E1 & E2, 45 Center Drive, Bethesda, MD 20892.
Open: September 11, 2009, 8:30 a.m. to adjournment.
Agenda: For the discussion of program policies and issues,
opening remarks, report of the Director, NIGMS, and other business
of the Council.
Place: National Institutes of Health, Natcher Building,
Conference Rooms E1 & E2, 45 Center Drive, Bethesda, MD 20892.
Contact Person: Ann A. Hagan, PhD, Associate Director for
Extramural Activities, NIGMS, NIH, DHHS, 45 Center Drive, Room
2AN24H, MSC6200, Bethesda, MD 20892-6200. (301) 594-4499.
hagana@nigms.nih.gov.
Any interested person may file written comments with the
committee by forwarding the statement to the Contact Person listed
on this notice. The statement should include the name, address,
telephone number and when applicable, the business or professional
affiliation of the interested person.
In the interest of security, NIH has instituted stringent
procedures for entrance onto the NIH campus. All visitor vehicles,
including taxicabs, hotel, and airport shuttles will be inspected
before being allowed on campus. Visitors will be asked to show one
form of identification (for example, a government-issued photo ID,
driver's license, or passport) and to state the purpose of their
visit.
Information is also available on the Institute's/Center's home
page: https://www.nigms.nih.gov/about/advisory_council.html, where
an agenda and any additional information for the meeting will be
posted when available.
(Catalogue of Federal Domestic Assistance Program Nos. 93.375,
Minority Biomedical Research Support; 93.821, Cell Biology and
Biophysics Research; 93.859, Pharmacology, Physiology, and
Biological Chemistry Research; 93.862, Genetics and Developmental
Biology Research; 93.88, Minority Access to Research Careers; 93.96,
Special Minority Initiatives, National Institutes of Health, HHS)
Dated: August 10, 2009.
Jennifer Spaeth,
Director, Office of Federal Advisory Committee Policy.
[FR Doc. E9-19663 Filed 8-17-09; 8:45 am]
BILLING CODE 4140-01-M
